Chabrier-Roselló Yeissa, Foster Thomas H, Pérez-Nazario Nelissa, Mitra Soumya, Haidaris Constantine G
Department of Microbiology and Immunology, Center for Oral Biology, University of Rochester Medical Center, New York 14642, USA.
Antimicrob Agents Chemother. 2005 Oct;49(10):4288-95. doi: 10.1128/AAC.49.10.4288-4295.2005.
Treatment of mucocutaneous and cutaneous Candida albicans infections with photosensitizing agents and light, termed photodynamic therapy (PDT), offers an alternative to conventional treatments. Initial studies using the clinically approved photosensitizer Photofrin demonstrated the susceptibility of C. albicans to its photodynamic effects. In the present study, we have further refined parameters for Photofrin-mediated photodynamic action against C. albicans and examined whether mechanisms commonly used by microorganisms to subvert either antimicrobial oxidative defenses or antimicrobial therapy, including biofilm formation, were operative. In buffer and defined medium, germ tubes preloaded with Photofrin retained their photosensitivity for up to 2 hours, indicating the absence of degradation or export of Photofrin by the organism. The addition of serum resulted in a gradual loss of photosensitivity over 2 hours. In contrast to an adaptive response by germ tubes to oxidative stress by hydrogen peroxide, there was no adaptive response to singlet oxygen-mediated stress by photodynamic action. C. albicans biofilms were sensitive to Photofrin-mediated phototoxicity in a dose-dependent manner. Finally, the metabolic activity of C. albicans biofilms following photodynamic insult was significantly lower than that of biofilms treated with amphotericin B for the same time period. These results demonstrate that several of the mechanisms microorganisms use to subvert either antimicrobial oxidative defenses or antimicrobial therapy are apparently not operative during Photofrin-mediated photodynamic treatment of C. albicans. These observations provide support and rationale for the continued investigation of PDT as an adjunctive, or possibly alternative, mode of therapy against cutaneous and mucocutaneous candidiasis.
用光敏剂和光治疗黏膜皮肤和皮肤白色念珠菌感染,即光动力疗法(PDT),为传统治疗提供了一种替代方法。最初使用临床批准的光敏剂卟吩姆钠的研究表明白色念珠菌对其光动力效应敏感。在本研究中,我们进一步优化了卟吩姆钠介导的针对白色念珠菌的光动力作用参数,并研究了微生物用于颠覆抗菌氧化防御或抗菌治疗的常用机制(包括生物膜形成)是否起作用。在缓冲液和限定培养基中,预先加载卟吩姆钠的芽管在长达2小时内保持其光敏性,表明该生物体不存在卟吩姆钠的降解或输出。加入血清导致光敏性在2小时内逐渐丧失。与芽管对过氧化氢介导的氧化应激的适应性反应不同,对光动力作用介导的单线态氧应激没有适应性反应。白色念珠菌生物膜对卟吩姆钠介导的光毒性呈剂量依赖性敏感。最后,光动力损伤后白色念珠菌生物膜的代谢活性明显低于同期用两性霉素B处理的生物膜。这些结果表明,微生物用于颠覆抗菌氧化防御或抗菌治疗的几种机制在卟吩姆钠介导的白色念珠菌光动力治疗过程中显然不起作用。这些观察结果为继续研究光动力疗法作为治疗皮肤和黏膜念珠菌病的辅助或可能的替代治疗方式提供了支持和理论依据。